Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05285540 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia
A Phase 1 study, sponsored by Design Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT05285540 is a Phase 1 study that has completed, run by Design Therapeutics. The registered enrollment target is 39 participants.
The verdict
NCT05285540, a Phase 1 study, has completed, sponsored by Design Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of intravenous DT-216 in adult patients with Friedreich Ataxia. This single ascending dose study is randomized, double-blind, placebo-controlled.
Interventions
- DRUG DT-216
- DRUG DT-216 matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2022-03-11 |
| Est. Completion | 2022-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05285540
The ClinicalTrials.gov registry entry for NCT05285540 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Design Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DT-216 is the first listed.
NCT05285540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05285540 about?
NCT05285540 is a clinical study titled "Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of intravenous DT-216 in adult patients with Friedreich Ataxia. This single ascending dose study is randomized, double-blind, placebo-controlled.
What is the current status of trial NCT05285540?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2022-03-11. Estimated completion is 2022-12-19.
What interventions are being tested in trial NCT05285540?
The interventions under investigation include: DT-216 (DRUG), DT-216 matching Placebo (DRUG).
Who is sponsoring clinical trial NCT05285540?
This trial is sponsored by Design Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.